Robert Gould

Robert is an Operating Partner at Khosla Ventures with a focus on health care. He has over 30 years of industry and management experience. Robert serves on the boards of Faeth Therapeutics, Fulcrum Therapeutics, Turnstone Biologics, HemoShear Therapeutics, and Spring Arbor University.

Prior to joining Khosla Ventures, Robert was President and Chief Executive Officer of Fulcrum Therapeutics from 2016 the year the company was founded until his retirement in March 2021. From 2010 to 2015, Robert served as president and CEO of Epizyme, an oncology drug discovery, and development company. Prior to joining Epizyme, Robert served as the director of novel therapeutics at the Broad Institute of MIT and Harvard from 2006 to 2010. Robert began his career at Merck where he held a variety of leadership positions over 23 years, culminating in his role as vice president, of licensing, and external research.

Robert holds a bachelor’s degree in chemistry from Spring Arbor University and a Ph.D. in biochemistry from the University of Iowa. He completed postdoctoral studies at Johns Hopkins University.